The 2019 novel coronavirus disease (COVID‐19) now is considered a global public health
emergency. One of the unprecedented challenges is defining the optimal therapy for those …

Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

The pandemic caused by SARS-CoV-2 has cost millions of lives and tremendous
social/financial loss. The virus continues to evolve and mutate. In particular, the recently …

Background Patients with kidney failure on dialysis or after renal transplantation have a high
risk for severe COVID-19 infection, and vaccination against SARS-CoV-2 is the only …

Abstract Rationale: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses
a threat to humanity. However, no specific therapy has been established for this disease yet …

Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …

Background Although several studies have assessed the safety, efficacy, and effectiveness
of interventions in treating the COVID-19, many of them have limitations that can have an …

All authors (SG Rothrock, KD Weber, M. Barneck, PA Giordano) were involved in conception
of study, design of the study, data collection and abstraction, drafting and revision of the …

Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses
two-fold drug development problems. First, the role of ACE2 itself is still a matter of …